Niagen Bioscience, Inc. Stock Price
- 3 Narratives written by author
- 1 Comments on narratives written by author
- 73 Fair Values set on narratives written by author
NAGE Community Narratives
Niagen IV Launch And E-commerce Growth Will Strengthen Future Prospects
Expanding NAD Category And Clinical Pipeline Will Drive Powerful Long-Term Upside
NAD Market Competition And Regulatory Risks Will Challenge Margins Yet Support Long-Term Healthy Aging Demand
Expanding NAD Category And Clinical Pipeline Will Drive Powerful Long-Term Upside
View narrativeNiagen IV Launch And E-commerce Growth Will Strengthen Future Prospects
View narrativeNAD Market Competition And Regulatory Risks Will Challenge Margins Yet Support Long-Term Healthy Aging Demand
View narrativeTrending Discussion
No trending discussion available.
Recently Updated Narratives
NAGE: Longevity And GLP-1 Wellness Tailwinds Will Support Future Upside
NAGE: Rare Disease Drug Designations Will Drive Future Longevity Upside
NAGE: Injectables And Expanded Clinical Access Will Support Future Buyback Upside
Snowflake Analysis
Niagen Bioscience, Inc. Key Details
About NAGE
- Founded
- 1999
- Employees
- 117
- CEO
- Website
View website
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-grade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and authorized healthcare practitioners resellers. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.